Myeloproliferative Neoplasm clinical trials

Explore recruiting myeloproliferative neoplasm clinical trials.

Recruiting myeloproliferative neoplasm studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Myeloproliferative Neoplasm trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera

Spain, Portugal, Belgium, Netherlands, Germany, Hungary +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Long-term study evaluating the effect of givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

HOVON 172 MF: A phase 1b/2 trial with tasquinimod in patients with myelofibrosis (primary, post-PV or post-ET) refractory to or intolerant for JAK2 inhibition: the TasqForce trial

Germany, Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms.

Norway, Germany, France, Italy

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 3, Double-Blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

Germany, Czechia, Romania, Ireland, Austria, Greece +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-Label Clinical Trial of RVU120 as Monotherapy and in Combination with Ruxolitinib in Patients with Intermediate or High-Risk, Primary or Secondary Myelofibrosis (POTAMI-61)

Poland, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Myeloproliferative Neoplasm trials by city

Myeloproliferative Neoplasm in Toronto Myeloproliferative Neoplasm in Vancouver Myeloproliferative Neoplasm in Montreal Myeloproliferative Neoplasm in Calgary Myeloproliferative Neoplasm in Edmonton Myeloproliferative Neoplasm in Ottawa Myeloproliferative Neoplasm in Winnipeg Myeloproliferative Neoplasm in Quebec City Myeloproliferative Neoplasm in Hamilton Myeloproliferative Neoplasm in Kitchener Myeloproliferative Neoplasm in London Myeloproliferative Neoplasm in Halifax Myeloproliferative Neoplasm in New York Myeloproliferative Neoplasm in Los Angeles Myeloproliferative Neoplasm in Chicago Myeloproliferative Neoplasm in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease